Who is sponsoring NCT02133183?

NCT02133183 is sponsored by National Cancer Institute (NCI).

What drugs are being tested in NCT02133183?

Interventions in NCT02133183: Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib, Therapeutic Conventional Surgery.

What condition does NCT02133183 study?

NCT02133183 studies Glioblastoma, Gliosarcoma.

Is NCT02133183 still recruiting?

NCT02133183 is currently terminated. Last updated 4 April 2024.

Last reviewed 2024-04-04 · How we verify

NCT02133183

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

Terminated Phase 1 Last updated 4 April 2024

What this trial tests

Phase 1 trial testing Laboratory Biomarker Analysis in Glioblastoma in 40 participants. Terminated before completion.

Timeline

2 July 2014

Primary endpoint
31 January 2020

31 October 2023

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	2 July 2014
Primary completion	31 January 2020
Estimated completion	31 October 2023
Sites	10 locations across United States

Drugs / interventions tested

Laboratory Biomarker Analysis — full drug profile →
Pharmacological Study — full drug profile →
Sapanisertib — full drug profile →
Therapeutic Conventional Surgery

Conditions studied

Glioblastoma — all drugs for Glioblastoma →
Gliosarcoma — all drugs for Gliosarcoma →

Sponsor

National Cancer Institute (NCI)

Who can join

18 and older, any sex, with Glioblastoma or Gliosarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This partially randomized pilot phase I trial studies how much sapanisertib reaches the brain tumor and how well it works when given before and after surgery in treating patients with glioblastoma that has grown or come back and requires surgery. Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Wen PY, Weller M, Lee EQ, Alexander BM, et al · · 2020 · cited 908× · PMID 32328653 · DOI 10.1093/neuonc/noaa106
Current Challenges and Opportunities in Treating Glioblastoma.
Shergalis A, Bankhead A, Luesakul U, Muangsin N, et al · · 2018 · cited 612× · PMID 29669750 · DOI 10.1124/pr.117.014944
Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs.
Lee CH, Yu CC, Wang BY, Chang WW. · · 2016 · cited 128× · PMID 26527320 · DOI 10.18632/oncotarget.6261
The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
Miyahara H, Yadavilli S, Natsumeda M, Rubens JA, et al · · 2017 · cited 53× · PMID 28450157 · DOI 10.1016/j.canlet.2017.04.019
Treating recurrent glioblastoma: an update.
Kamiya-Matsuoka C, Gilbert MR. · · 2015 · cited 52× · PMID 25768333 · DOI 10.2217/cns.14.55
mTORC1-Mediated Inhibition of 4EBP1 Is Essential for Hedgehog Signaling-Driven Translation and Medulloblastoma.
Wu CC, Hou S, Orr BA, Kuo BR, et al · · 2017 · cited 51× · PMID 29103956 · DOI 10.1016/j.devcel.2017.10.011
Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review.
Vogelbaum MA, Krivosheya D, Borghei-Razavi H, Sanai N, et al · · 2020 · cited 50× · PMID 32598442 · DOI 10.1093/neuonc/noaa149
Inhibiting 4EBP1 in Glioblastoma.
Fan QW, Nicolaides TP, Weiss WA. · · 2018 · cited 40× · PMID 28696243 · DOI 10.1158/1078-0432.ccr-17-0042

Verify or expand the search:

Other trials of Laboratory Biomarker Analysis

Trials testing the same drug.

NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
NCT05558904 — An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cance · Phase 1, PHASE2 · recruiting
NCT05564650 — Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome · Phase 1 · active not recruiting
NCT05396859 — Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia · Phase 1 · active not recruiting

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02133183 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 4 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02133183.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing